Brenus Pharma Raises €11 Million in Series A Extension

Brenus Pharma, a biotechnology company specializing in cancer immunotherapy, has successfully raised €11 million in a Series A extension round. This funding endeavor aims to support the advancement of its innovative immunotherapy platform, particularly targeting difficult-to-treat solid tumors.

Investors and Participants

The latest funding round saw contributions from a diverse group of investors, including Angelor, UI Investissement, Crédit Agricole, Noshaq, Orsa, BIO JAG, Bpifrance, Sambrinvest, and Korea Omega Investment Corp. Notably, Sambrinvest and Korea Omega Investment Corp have joined as new investors, expanding Brenus Pharma's reach to the European and Asia-Pacific markets.

Focus on Advancing Cancer Treatment

The funds are earmarked for completing the Phase I clinical program for Brenus Pharma's lead therapy, STC-1010. This investigational therapy is designed to treat microsatellite-stable metastatic colorectal cancer (MSS mCRC), a form of colorectal cancer known for its resistance to some existing immunotherapies. The therapy is currently under evaluation in clinical trials, with the identifier NCT06934538.

Use of Funds

  • Clinical Trials: The primary focus of the funds will be on advancing the clinical trials of STC-1010.
  • Platform Development: Further development of Brenus Pharma's proprietary in vivo immunotherapy platform is also planned.

Leadership and Vision

Paul Bravetti, the Chief Executive Officer of Brenus Pharma, emphasized the significance of this funding round in reducing development risks and enhancing the company's ability to meet clinical and regulatory milestones. The goal is to stimulate a broader immune response capable of adapting to tumor changes over time, thereby improving treatment outcomes for patients with solid tumors.

Brenus Pharma continues to innovate in the field of immuno-oncology, with its off-the-shelf therapies designed for broader patient application and increased efficacy against evolving cancer cells. As the company moves forward, it remains committed to addressing the challenges associated with treating resistant cancer forms.